Page 14 - Flipbook
P. 14
Androgen Signaling Inhibition Therapy Development
2006 2012-2020
2009
Endocrine mediated Paracrine Genomic/ Non
progression /Intracrine Genomic Driven
Progression Resistance mCRPC
Abiraterone Enzalutami Unmet Needs:
de
testosterone testosterone ➢Effective therapeutic strategies for
Endocri Localized High Risk Disease
ne
organs
➢ Predictors of Outcome to guide
2017 -2019 mHNPC
Progress Report: Abiraterone therapy selection
Androgen Signaling Inhibition 2011-2012 Enzalutamide
Apalutamide
prevailing therapeutic strategy mCRPC 2018 -2019
Abiraterone
in advanced Prostate Cancer Enzalutamide nmCRPC
✓ Reproducible outcomes Enzalutamide
Apalutamide
✓ Earlier is better Darolutamide
✓ ..more may be less..
